Note 1 - Organization and Nature of Operations (Details Textual) $ / shares in Units, $ in Thousands							3 Months Ended
	May 12, 2025 USD ($) $ / shares shares	Apr. 22, 2025 USD ($) $ / shares shares	Jan. 24, 2025 USD ($) shares	Jan. 24, 2025	Jan. 14, 2025 USD ($) shares	Jul. 15, 2024 $ / shares shares	Mar. 31, 2025 USD ($) $ / shares shares	Mar. 31, 2024 USD ($)	Feb. 17, 2025	Dec. 31, 2024 USD ($) $ / shares shares
Common Stock, Shares Authorized (in shares) | shares						30,000,000	60,000,000			60,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares						$ 0.0001	$ 0.0001			$ 0.0001
Net Income (Loss) Attributable to Parent							$ (4,045)	$ (2,675)
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation							(2,338)	$ (1,942)
Retained Earnings (Accumulated Deficit)							(296,397)			$ (292,352)
Cash and Cash Equivalent							450			$ 2,873
Stock Issued During Period, Value, Purchase of Assets							$ 113
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares							$ 0.0001			$ 0.0001
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares
Subsequent Event [Member] | Series L Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares	2,858
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares	$ 0.5
Subsequent Event [Member] | May 2025 PIPE Financing [Member]
Proceeds from Issuance or Sale of Equity	$ 1,500
Payments of Stock Issuance Costs	$ 200
Subsequent Event [Member] | May 2025 PIPE Financing [Member] | PIPE Units [Member]
Stock Issued During Period, Shares, New Issues (in shares) | shares	1,500
Units Issued, Series B Preferred Shares Per Unit	1
Subsequent Event [Member] | May 2025 PIPE Financing [Member] | Series B Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares) | shares	1,500
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares	$ 0.0001
Subsequent Event [Member] | May 2025 PIPE Financing [Member] | Series B Preferred Stock and Series B Preferred Stock Included in Units [Member]
Stock Issued During Period, Shares, New Issues (in shares) | shares	3,000
Stock Issued During Period, Value, New Issues	$ 3,000
PeriKard, LLC [Member]
Asset Acquisition, Percentage of Membership Interest Acquired			100.00%	100.00%	100.00%
Stock Issued During Period, Shares, Purchase of Assets (in shares) | shares			275,000		275,000
Stock Issued During Period, Value, Purchase of Assets			$ 113		$ 113
Royalty Percentage				10.00%	10.00%
Royalty, Term (Year)			5 years	5 years	5 years
Cardionomic's Late-stage Treatment for Acute Decompensated Heart Failure [Member] | Subsequent Event [Member]
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares		$ 0.0001
Stock Issued During Period, Shares, Purchase of Assets (in shares) | shares		1,000,000
Stock Issued During Period, Value, Purchase of Assets		$ 310
Debt Instrument, Face Amount		$ 1,500
Debt Instrument, Interest Rate, Stated Percentage		4.00%
Debt Instrument, Term (Year)		3 years
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio						10
Cardionomix Inc. [Member]
Subsidiary, Ownership Percentage, Parent									82.00%
Cardionomix Inc. [Member] | Chief Executive Officer and Chairman of the Board [Member]
Subsidiary, Ownership Percentage, Parent									12.00%
Cardionomix Inc. [Member] | Certain Business Associates of the CEO [Member]
Subsidiary, Ownership Percentage, Parent									6.00%